Regeneron Pharmaceuticals Inc (REGN)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 77.30% | 78.23% | 80.28% | 85.66% | 83.42% |
| Operating profit margin | 28.10% | 31.03% | 39.12% | 55.87% | 42.38% |
| Pretax margin | 33.66% | 32.19% | 40.11% | 58.23% | 45.15% |
| Net profit margin | 31.07% | 30.31% | 35.81% | 50.43% | 41.62% |
The Gross profit margin of Regeneron Pharmaceuticals Inc has shown a slight fluctuation over the years, starting at 83.42% in December 31, 2020, increasing to 85.66% by December 31, 2021, and then dipping to 77.30% by December 31, 2024. This indicates the company's ability to generate profit from its core operations, although there has been a decline in profitability by the end of the period.
In terms of Operating profit margin, there has been a significant increase from 42.38% in December 31, 2020, to 55.87% by December 31, 2021. However, the margin has shown a downward trend in the following years, reaching 28.10% by December 31, 2024. This suggests that the company may be facing challenges in controlling its operating expenses relative to its revenue.
Looking at the Pretax margin, there was a notable rise from 45.15% in December 31, 2020, to 58.23% by December 31, 2021. Subsequently, the margin decreased to 33.66% by December 31, 2024. This indicates fluctuations in the company's profitability before accounting for taxes, highlighting the need for efficient tax management strategies.
Finally, the Net profit margin of Regeneron Pharmaceuticals Inc has shown a similar trend to the pretax margin, with an increase in profitability from 41.62% in December 31, 2020, to 50.43% by December 31, 2021, followed by a decline to 31.07% by December 31, 2024. This suggests that the company's bottom line profitability has been impacted by various factors over the years.
Overall, while the company has consistently maintained high levels of gross profit margin, there are fluctuations in operating, pretax, and net profit margins, indicating the need for cost management and operational efficiency improvements to sustain profitability in the long term.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 10.57% | 12.23% | 16.22% | 35.18% | 20.84% |
| Return on assets (ROA) | 11.69% | 11.95% | 14.85% | 31.75% | 20.47% |
| Return on total capital | 12.73% | 15.28% | 19.96% | 45.22% | 29.74% |
| Return on equity (ROE) | 15.03% | 15.22% | 19.14% | 43.03% | 31.86% |
Regeneron Pharmaceuticals Inc's profitability ratios show a fluctuating trend over the five-year period from December 31, 2020, to December 31, 2024.
- Operating return on assets (Operating ROA) improved from 20.84% in 2020 to 35.18% in 2021 before declining to 10.57% in 2024. This indicates that the company's ability to generate operating profit from its assets was strongest in 2021 but weakened in the subsequent years.
- Return on assets (ROA) followed a similar pattern, starting at 20.47% in 2020, peaking at 31.75% in 2021, and then gradually declining to 11.69% in 2024. This ratio reflects the overall efficiency of the company in generating profits from its total assets.
- Return on total capital also displayed an upward trend from 29.74% in 2020 to 45.22% in 2021, followed by a continuous decrease to 12.73% in 2024. This ratio indicates how well the company can generate earnings from its total invested capital.
- Return on equity (ROE) started at 31.86% in 2020, reached its highest point at 43.03% in 2021, and then decreased to 15.03% in 2024. ROE measures the return on shareholder equity and reflects the company's profitability from the shareholders' perspective.
Overall, Regeneron Pharmaceuticals Inc's profitability ratios have shown variability over the years, with periods of improvement followed by declines. It is important for investors and stakeholders to monitor these ratios closely to assess the company's financial health and performance.